WEKO3
アイテム
2010 AALAS National Meeting
https://repo.qst.go.jp/records/70277
https://repo.qst.go.jp/records/70277b9a1d2b8-7039-457c-ac35-b0c0c543280c
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2010-10-18 | |||||
| タイトル | ||||||
| タイトル | 2010 AALAS National Meeting | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Kokubo, Toshiaki
× Kokubo, Toshiaki× Nishikawa, Tetsu× Matsushita, Satoru× 小久保 年章× 西川 哲× 松下 悟 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Pasteurella pneumotropica, a Gram-negative opportunistic pathogen, is frequently isolated from the respiratory organs and digestive tracts of clinically normal conventional mice. Oral or subcutaneous treatment with enrofloxacin, an antibiotic, at a daily dose of 25.5 mg/kg for 2 weeks is effective in eliminating P. pneumotropica. However, the drawbacks of this treatment include substituted microbism and inhibited growth of indigenous fungi in the mouth. We therefore examined whether reducing the enrofloxacin treatment duration and dosage could eliminate P. pneumotropica from mice and eliminate these drawbacks. Healthy C3H/HeMsNrs (TLR4-competent) and C.B-17/Icr- Prkdcscid/JclNrs mice were intranasally inoculated with 1 X 107 P. pneumotropica. Twenty-two days after inoculation, the mice were subcutaneous injected with enrofloxacin once a day for 3 days at doses ranging from 3 to 300 mg/kg. Day 22 was chosen for treatment initiation because in a preliminary examination P. pneumotropica was detected in nasal samples by PCR assay 21 days after inoculation. Seven days after the completion of treatment, all mice were sacrificed and oral, nasal, and tracheal swabs were collected. Each swab sample was plated directly onto blood agar and incubated. To identify P. pneumotropica among the isolates, PCR assay was used to identify the 16S rRNA gene. The lungs and skin were examined histopathologically. Pasteurella pneumotropica was not detected, even in the minimum-dose group (3 mg/kg), in C3H/HeMsNrs mice. In the 100- and 300-mg/kg dose groups, induration or inflammation was observed in the skin at the injection site. In C.B-17/Icr- Prkdcscid/JclNrs mice, P. pneumotropica was detected at enrofloxacin doses of 3 and 10 mg/kg, and these mice developed pneumonia. Because of skin inflammation, higher doses were not tested. Subcutaneous administration of enrofloxacin at a dose of 3 mg/kg for 3 days can successfully eradicate latent infection of P. pneumotropica in immunocompetent mice. Further investigation is needed to clarify the lack of efficacy of the same treatment in immunodeficient mice. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 2010 AALAS National Meeting | |||||
| 発表年月日 | ||||||
| 日付 | 2010-10-14 | |||||
| 日付タイプ | Issued | |||||
